IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+37.65%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$241M
AUM Growth
+$241M
(+20%)
Cap. Flow
-$3.2M
Cap. Flow
% of AUM
-1.33%
Top 10 Holdings %
Top 10 Hldgs %
54.79%
Holding
92
New
13
Increased
8
Reduced
23
Closed
11
Top Buys
| 1 |
Vaxcyte
PCVX
|
$12M |
| 2 |
Biohaven
BHVN
|
$11.6M |
| 3 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$6.35M |
| 4 |
BioXcel Therapeutics
BTAI
|
$5.37M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$4.9M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$12.9M |
| 2 |
Ardelyx
ARDX
|
$5.13M |
| 3 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$5.03M |
| 4 |
SAGE
Sage Therapeutics
SAGE
|
$3.43M |
| 5 |
Altimmune
ALT
|
$3.27M |
Sector Composition
| 1 | Healthcare | 99.4% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $31.8M | 7.67% | 288,926 +57,745 | +25% | +$6.35M |
|
2
Immunovant
IMVT
$2.56B
| $17.2M | 4.14% | 966,700 +155,000 | +19% | +$2.75M |
|
|
3
Vaxcyte
PCVX
$4B
| $12M | 2.89% | +250,000 | New | +$12M |
|
4
Celldex Therapeutics
CLDX
$1.47B
| $11.9M | 2.88% | 267,476 -50,000 | -16% | -$2.23M |
|
5
Esperion Therapeutics
ESPR
$448M
| $11.8M | 2.84% | 1,891,147 -240,000 | -11% | -$1.5M |
|
|
6
Biohaven
BHVN
$1.63B
| $11.6M | 2.8% | +837,500 | New | +$11.6M |
|
|
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $10.2M | 2.45% | 89,219 +15,000 | +20% | +$1.71M |
|
8
Astria Therapeutics
ATXS
$349M
| $10.1M | 2.43% | 675,176 -24,264 | -3% | -$361K |
|
|
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $8.07M | 1.95% | 377,021 -601,762 | -61% | -$12.9M |
|
10
Terns Pharmaceuticals
TERN
$609M
| $7.51M | 1.81% | 737,319 -166,800 | -18% | -$1.7M |
|
|
BLU
11
DELISTED
BELLUS Health Inc.
BLU
| $7.28M | 1.76% | 885,334 +35,200 | +4% | +$289K |
|
|
VRNA
12
Verona Pharma
VRNA
$9.16B
| $6.67M | 1.61% | 255,131 -60,000 | -19% | -$1.57M |
|
13
Xenon Pharmaceuticals
XENE
$2.98B
| $6.33M | 1.53% | 160,486 | – | – |
|
|
DCPH
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $6.02M | 1.45% | 367,119 -125,156 | -25% | -$2.05M |
|
15
89bio
ETNB
$1.34B
| $5.78M | 1.39% | 454,000 +254,000 | +127% | +$3.23M |
|
|
BLUE
16
DELISTED
bluebird bio
BLUE
| $5.62M | 1.36% | 812,628 +350,000 | +76% | +$2.42M |
|
|
17
BioXcel Therapeutics
BTAI
$59M
| $5.37M | 1.3% | +250,000 | New | +$5.37M |
|
18
Acadia Pharmaceuticals
ACAD
$4.38B
| $5.17M | 1.25% | 325,000 | – | – |
|
|
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.9M | 1.18% | +108,100 | New | +$4.9M |
|
|
20
Altimmune
ALT
$338M
| $4.5M | 1.09% | 273,432 -198,622 | -42% | -$3.27M |
|
21
Kezar Life Sciences
KZR
$28.9M
| $4.44M | 1.07% | 629,986 -98,600 | -14% | -$694K |
|
|
TCON
22
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $4.12M | 0.99% | 2,765,530 | – | – |
|
|
23
Ardelyx
ARDX
$1.53B
| $3.93M | 0.95% | 1,378,825 -1,800,000 | -57% | -$5.13M |
|
|
JBIO
24
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $3.75M | 0.9% | 127,921 -72,079 | -36% | -$2.11M |
|
25
Sarepta Therapeutics
SRPT
$1.78B
| $3.67M | 0.89% | 28,324 +11,515 | +69% | +$1.49M |
|